Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Danaher on Wednesday missed Wall Street estimates for fourth-quarter profit due to soft demand for tools and services used in drug development by its biotech and pharmaceutical clients. The company ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

Similar trends have been observed for companies that manufacture tools for production in the pharmaceutical and biotech ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

BMO Capital analyst Kostas Biliouris has maintained their bullish stance on LEGN stock, giving a Buy rating yesterday.Invest with Confidence: ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE ...